Home >> Books >> The 2012 Short Guide to Hepatitis C #11: The 2012 Short Guide to Hepatitis C 10.         References Download the entire book (PDF, 150 pages). Afdhal N, Dusheiko G, Giannini EG, et al. Final results of enable 1, a phase 3, multicenter study of eltrombopag as an adjunct for antiviral treatment of hepatitis c virus-related chronic liver disease associated with thrombocytopenia. Hepatology 2011;54:1427A-28A. Afdhal N, O'Brien C, Godofsky E. Valopicitabine alone or with PEG-interferon/ribavirin retreatment in patients with HCV-1 infection and prior non-reponse to PEGIFN/RBV: One-year results. J Hepatol 2007;46:S5. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterol 2004;126:1302-11. (Abstract) Afdhal NH, Dusheiko G, Giannini EG, et al. Final Results of ENABLE 1, a Phase 3, Multicenter Study of Eltrombopag as an Adjunct for Antiviral Treatment of Hepatitis C Virus-Related Chronic Liver Disease Associated With Thrombocytopenia. Hepatology 2011; 54:1427-8. Afdhal NH, McHutchison JG, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011; 53:336-45. (Abstract) Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other Flaviviridae viruses enter cells via low-density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-71. (Abstract) Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterol 2010;138:1112-22. (Abstract) Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C viurs core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatol 2010;52:421-429. (Abstract) Alberti A, Clumeck N, Collins S, et al. ECC Jury. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615-24. (Abstract) Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol 1995;22(1 Suppl):38-41. (Abstract) Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother 2008;52:4356-69. (Abstract) Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62. (Abstract) Amorosa VK, Slim J, Mounzer K, et al. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther. 2010;15:91-9. (Abstract) Anonymous. Boceprevir. Drugs R D 2010;10:203-10. (Abstract) Anonymous. Hepatitis C: RKI-Ratgeber Infektionskrankheiten. Epidemiologisches Bulletin 2004;17:141-5. Antaki N, Craxi A, Kamal S et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-55. (Abstract) Antonelli A, Ferri C, Pampana A, et al. Thyroid disorders in chronic hepatitis C. Am J Med 2004;117:10-13. (Abstract) Aroldi A, Lampertico P, Montagnino G, et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005;79:1132-6. (Abstract) Ascione A, De Luca M, Tartaglione MT et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010;138:116-22. (Abstract) Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516.e1. (Abstract) Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17. (Abstract) Bacon BR, Gordon SC, Lawitz E, et al. HCV respond-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus pegintron (pegintron alfa-2b) / ribavirin. Hepatol 2010a;52:S430. Bacon BR, Shiffman ML, Lim JK, et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 naive patients: week 12 sustained virologic response rate. J Hepatol 2010b;52:S463. Bani-Sadr F, Denoeud L, Morand P, et al and the Agence Nationale pour la Recherche contre le SIDA et les Hépatites Virales HC02-Ribavic Study Team. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007;45:123-5. (Abstract) Barnard RJ, Zeuzem S, Vierling J, Sulkowski M, Manns M, Long J. Analysis of resistance-associated amino acid variants in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical trials. Hepatology 2011;54:164. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004;63:71-180. (Abstract) Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007;8:614-34. (Abstract) Beinhardt S, Aberle JH, Strasser M et al. Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection. Gastroenterology 2012;142:78-85.e2. (Abstract) Bellecave P, Gouttenoire J, Gajer M et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009;50:46-55. (Abstract) Benhamou Y, Moussalli J, Ratziu V, et al. Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 4 hepatitis-C patients: final results of study C210. Hepatol 2010;52:S719. Berg T, Andreone P, Pol S, et al. Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III realize study. Hepatology 2011;54:375A-376A. Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, et al. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology 2003;37:1359-67. (Abstract) Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterol 2006;130:1086-97. (Abstract) Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-77. (Abstract) Bevilacqua E, Fabris A, Floreano P, et al and the EPHN collaborators. Genetic factors in mother-to-child transmission of HCV infection. Virology 2009;Jul 20;390:64-70. (Abstract) Boesecke C, Vogel M. HIV and hepatitis C co-infection: acute HCV therapy. Curr Opin HIV AIDS. 2011;6:459-64. (Abstract) Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90. (Abstract) Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol 2006;1:103-12. (Abstract) Brainard DM, Petry A, Van Dyck K, et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatol 2010;52:S706. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, Negro F. Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323-28. (Abstract) Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2001;24:701-08. (Abstract) Bruix J, Poynard T, Colombo M, et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 2011;140:1990-9. (Abstract) Bruno S, Vierling JM, Esteban R, et al. Boceprevir in addition to standard of care enhanced svr in hepatitis c virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of sprint-2 and respond-2 studies. J Hepatol 2011;54:S4-S4. Bukh J, Miller RH, Purcell RH. Biology and genetic heterogeneity of hepatitis C virus. Clin Exp Rheumatol 1995; Suppl 13:S3-7. (Abstract) Buti M, Lurie Y, Zakharova NG, et al. Extended Treatment Duration in Chronic Hepatitis C Genotype 1-Infected Slow Responders: Final Results of the Success Study. J Hepatol 2009;50:S58-S58. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6. (Abstract) Cacoub P, Poynard T, Ghillani P, et al and the MULTIVIRC group. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999;42:2204-12. (Abstract) Cacoub P, Renou C, Rosenthal E, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. Groupe d' Etude et de Recherche en Medicine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine 2000;79:47-56. (Abstract) Calleja JL, Albillos A, Moreno-Otero R, et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 1999;13:1179-86. (Abstract) Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-73. (Abstract) Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 in HCV genotype 1b-infected null responders. Hepatology 2011, in press. (Abstract) Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatol 2007;46:22-31. (Abstract) Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7. (Abstract) Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132-7. (Abstract) Child CGI, Turcotte JG. Surgery and Portal Hypertension. In: Child CGI, ed. The Liver and portal hypertension. Philadelphia: WB Saunders; 1964:50-64. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008;23:512-20. (Abstract) Chu CM, Sheen IS, Liaw YF. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology 1994;107:189-95. (Abstract) Chu CM, Yeh CT, Liaw YF. Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut 1999;45:613-7. (Abstract) Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol 1998;36:2084-6. (Abstract) Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy. Antivir Ther 2005;10:125-33. (Abstract) Colin C, Lanoir D, Touzet S, et al. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001;8:87-95. (Abstract) Cooper C, Lawitz E, Ghali P, et al. Antiviral activity of the non-nucleoside polymerase inhibitor, VCH-759, in chronic hepatitis C patients: Results from a randomized, double-blind, placebo-controlled, ascending multiple dose study. Hepatol 2007;46:S864. Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006;44:291-301. (Abstract) Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31 Suppl 2:30-60. (Abstract) Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. Curr Gastroenterol Rep 2002;4:23-30. (Abstract) Costelloe SJ, Wassef N, Schulz J, et al. Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy. Clin Endocrinol (Oxf) 2010;73:249-56. (Abstract) Craxì A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med 2008;29:85-95. (Abstract) Cribier B, Rey D, Schmitt C, et al. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995;9:1131-36. (Abstract) Crockett SD and Keeffe EB Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005;4:13. (Abstract) Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005;4:13. (Abstract) Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatol 2004;40:1260-65. (Abstract) Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatol 2008;47:35-42. (Abstract) Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-53. (Abstract) Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983-91. (Abstract) Danta M, Semmo N, Fabris P, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008;197:1558-66. (Abstract) Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-31. (Abstract) Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011;53:14-22. (Abstract) Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21, 521.e1-6. (Abstract) Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6. (Abstract) Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52. (Abstract) de Ledinghen V, Trimoulet P, Mannant PR, et al. Outbreak of hepatitis C virus infection during sclerotherapy of varicose veins: long-term follow-up of 196 patients (4535 patient-years). J Hepatol 2007;46:19-25. (Abstract) Deterding K, Gruener N, Wiegand J, et al. Early Versus Delayed Treatment of Acute Hepatitis C: The German Hep-Net Acute Hcv-Iii Study - a Randomized Controlled Trial. J Hepatol 2009;50:S380-S380. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10. (Abstract) Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-41. (Abstract) Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review. Am J Psychiatry 2000;157:867-76. (Abstract) Dore GJ, Matthews GV, Rockstroh J. Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS. 2011;6:508-13. (Abstract) Dorner M, Horwitz JA, Robbins JB, et al. A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208-11. (Abstract) Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004;40:669-74. (Abstract) Duvet S, Op de Beeck A, Cocquerel L, et al. Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line. Glycobiology 2002;12:95-101. (Abstract) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64. (PDF: http://goo.gl/xun82) Egger D, Wölk , Gosert R, et al. Expression of hepatitis C virus proteins induce distinct membrane alterations including candidate viral replication complex. J Virol 2002;76:5974-84. (Abstract) Erhardt A, Deterding K, Benhamou Y, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther 2009;14:23-32. (Abstract) European AIDS Clinical Society. EACS Guidelines. Version 6.0, October 2011. (PDF: http://goo.gl/HmfG5)    Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007;446:801-05. (Abstract) Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Rev Gastroenterol Disord 2004;4:S31-38. (Abstract) Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009;51:446-57. (Abstract) Fabrizi F, Lunghi G, Messa P, Martin P. Therapy of hepatitis C virus-associated glomerulonephritis: current approaches. J Nephrol 2008;21:813-825. (Abstract) Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther 2011;33:1162-72. (Abstract) Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47. (Abstract) Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010;464:405-8. (Abstract) Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterol 2008;135:451-58. (Abstract) Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterol 2008;135:1561-7. (Abstract) Ferri C, Antonelli A, Mascia MT, et al. B cells and mixed cryoglobulinemia. Autoimmun Rev 2007;7:114-20. (Abstract) Ferri C, Sebastiani M, Guiggiolo D, et al. Mixed cryoglobulinaemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74. (Abstract) Flamm S, Lawitz E, Jacobson I, et al. High sustained virologic response (SVR) among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir (BOC) plus peginterferon alfa-2a/ribavirin. J Hepatol 2011;54:S541-S542. Flisiak R, Feinman SV, Jablkowski M, et al. The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha 2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatol 2009;49:1460-8. (Abstract) Flisiak R, Horban A, Gallay P, et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatol 2008;47:817-26. (Abstract) Flisiak R, Pawlotsky JM, Crabbe R, Callistru PI, Kryczka W, Häussinger D. Once daily alisporivir (Debio025) plus pegIFNalfa2a/ribavirin results in superior sustained virologic response (SVR) in chronic hepatitis C genotype 1 treatment naive patients. J Hepatol 2011;54:24. Fong TL, Di Bisceglie AM, Waggoner JG, et al. The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. Hepatology 1991;14:64-7. (Abstract) Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatol 2007;46:640-8. (Abstract) Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-96. (Abstract) Forton DM, Taylor-Robinson SD, Thomas HC. Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat 2003;10:81-6. (Abstract) Foster GR, Hezode C, Bronowicki JP, et al. Activity of telaprevir alone or in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis-C patients: final results of study C209. J Hepatol 2010;52:S27. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-9.e1. (Abstract) Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations. Hepatology 2011, in press. (Abstract) Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82. (Abstract) Fukuda R, Ishimura N, Hamamoto S, et al. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. J Med Virol 2001;63:220-7. (Abstract) Fukuda R, Ishimura N, Niigaki M, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999;58:201-7. (Abstract) Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010;376:1467-75. (Abstract) Gane EJ, Stedman CA, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV Gt2 or Gt3. Hepatology 2011;54:18. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100. (Abstract) Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011;54:20-7. (Abstract) Garini G, Allegri L, Lannuzzella F, Vaglio A, Buzio C. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies. Acta Biomed 2007;78:51-59. (Abstract) Gastaminza P, Cheng G, Wieland S, et al. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol 2008;82:2120-29. (Abstract) Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatol 2009;49:1069-82. (Abstract) Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002;36(5 Suppl 1):S161-72.  (Abstract) Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterol 2003;125:80-88. (Abstract) Germi R, Crance JM, Garin D, et al. Cellular glycosaminglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002;68:206-15. (Abstract) Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-44. (Free full-text) Giannelli F, Moscarella S, Giannini C, Caini P, Monti M, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003;102:1196-201. (Abstract) Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in (Abstract) Gitto S, Micco L, Conti F, Andreone P, Bernardi M. Alcohol and viral hepatitis: A mini-review. Dig Liver Dis 2009;41:67-70. (Abstract) Gordon FD, Brown RS, Kwo P, et al. Peginterferon alfa-2b and ribavirin for hepatitis C recurrence post-orthotopic liver transplantation (OLT): Final results from the Protect study. J Hepatol 2010;52:S10-S11. Gordon SC, Lawitz EJ, Bacon BR, et al. Adherence to assigned dosing regimen and sustained virologic response among hepatitis c genotype 1 treatment-naive and peg/ribavirin treatment-failures treated with boceprevir plus peginterferon alfa-2b/ribavirin. J Hepatol 2011;54:S173-S174. Gotz HM, van Doormun G, Niesters HG, et al. A cluster with acute hepatitis C virus infection among men who have sex with men - results from contact tracing and public health implications. AIDS 2005;19:969-74. (Abstract) Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol 2011a;8:265-74. (Abstract) Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 2010;52:1216-24. (Abstract) Grebely J, Petoumenos K, Hellard M, et al; ATAHC Study Group. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52:1216-24. (Abstract) Grebely J, Pham ST, Matthews GV, et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology 2011b. [Epub ahead of print] (Abstract) Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C; a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55. (Abstract) Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2011. [Epub ahead of print] (Abstract) Heller TS, Saito J, Auerbach T, et al. An in vitro model of hepatitis C virion production. Proc Nat Acad Sci USA 2005;102:2579-83. (Abstract) Hendricks DA, Friesenhahn M, Tanimoto L, et al. Multicenter evaluation of the VERSANT HCV RNA qualitative assay for detection of hepatitis C virus RNA. J Clin Microbiol 2003;41:651-6. (Abstract) Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50. (Abstract) Hezode C, Hirschfield GM, Ghesquiere W, et al. BMS-790052, a NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-navie HCV-gentoype 1 or 4 patients: phase 2b AI444010 study interim week 12 results. Hepatology 2011;54:115. Hijikata M, Kato N, Ootsuyama Y, et al. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA 1991;88:5547-51. (Abstract) Hinrichsen H, Benhamou Y, Wedemeyer H, et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterol 2004;127:1347-55. (Abstract) HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004;164:2349-54. (Abstract) Hofmann WP, Dries V, Herrmann E, et al. Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. J Clin Virol 2005;32:289-93. (Abstract) Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26:15S-20S. (Abstract) Hraber P, Kuiken C, Yusim K. Evidence for human leukocyte antigen heterozygote advantage against hepatitis C virus infection. Hepatology 2007;46:1713-21. (Abstract) Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003;100:7271-76. (Abstract) Hung CH, Lee CM, Lu SN, et al. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and C virus infection. J Gastroenterol Hepatol 2005;20:727-32. (Abstract) INCIVO (telaprevir) EU SmPC 2011. PDF, 147 pages. Accessed on February 25, 2012. Jacobson IM, Catlett I, Marcellin P, et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the ADVANCE trial. J Hepatol 2011a;54:S542-S543. Jacobson IM, Gonzalez SA, Ahmed F, et al. A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Am J Gastroenterol 2005;100:2453-62. (Abstract) Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16. (Abstract) Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatmnet-naive patients: final results of phase 3 advance study. Hepatol 2010;52:S427. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-57. (Abstract) Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-43. (Abstract) Jardi R, Rodriguez F, Buti M, et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-10. (Abstract) Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatol 2006;43:954-60. (Abstract) Jensen DM, Wedemeyer H, Herring RW, et al. High rates of early viral response, promising safety profile and lack of resistance-related breakthrough in HCV Gt 1/4 patients treatment with RG7128 plus pegIFN alfa-2A (40kD)/RBV: planned week 12 interim analysis from the propel study. Hepatol 2010;52:S360. Jin F, Prestage GP, Matthews GV, Zablotska I, Rawstorne P, Kippax SC, Kaldor J, Grulich AE. Prevalence, incidence and risk factors for hepatitis C in homosexual men:Data from two cohorts of HIV negative and HIV positive men in Sydney, Australia. Sex Transm Infect. 2010; 86:25-8. Jin L, Peterson DL. Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA helicase. Arch Biochem Biophys 1995;323:47-53. (Abstract) Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha 2b and ribavirin therapy in chronic hepatitis C genotype 4; impact of treatment duration and viral. Gut. 2005;54:858-66. (Abstract) Kamar N, Rostaing L, Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 2006;69:436-39. (Abstract) Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011;54:1250-62. (Abstract) Kim DW, Gwack Y, Han JH, et al. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem Biophys Res Commun 1995;215:160-66. (Abstract) Kim JL, Morgenstern KA, Griffith JP, et al. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998;6:89-100. (Abstract) Kim JL, Morgenstern KA, Lin C, et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55. (Abstract) Kneteman NM, Howe AY, Gao T, et al. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatol 2009;49:745-52. (Abstract) Koch U and Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007;7:1302-29. (Abstract) Kraus MR, Schafer A, Al-Taie O, Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J Viral Hepat 2005;12:96-100. (Abstract) Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9. (Abstract) Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med 2001;345:375-6. (Abstract) Kraus MR, Schafer A, Schottker K, et al. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: A randomized, double-blind, placebo-controlled study. Gut 2008;57:531-6 (Abstract) Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatol 2008;48:1769-78. (Abstract) Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16. (Abstract) Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology 2010;52:1573-80. (Abstract) Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9. (Abstract) Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52. (Abstract) Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus peg/RBV in treatment-naive pateitns with HCV GT1: robust end of treatemnt response rates are sustained post-treatment. Hepatology 2011;54:113. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-69. (Abstract) Lenz O, Fevery B, Vigen L, et al. TMC435 in combination with peginterferon alpha-2a/ribavirin in treatment-naive patients infected with HCV genotype 1: virology analysis of the Pillar study. Hepatology 2011;54:985. Lesburg CA, Cable MB, Ferrari E, et al. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 1999;6:937-43. (Abstract) Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004;126:1024-9. (Abstract) Liaw YF, Lin SM, Sheen IS, et al. Acute hepatitis C virus superinfection followed by spontaneous HBeAg seroconversion and HBsAg elimination. Infection 1991;19:250-1. (Abstract) Liaw YF, Tsai SL, Chang JJ, et al. Displacement of hepatitis B virus by hepatitis C virus as the cause of continuing chronic hepatitis. Gastroenterology 1994;106:1048-53. (Abstract) Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000;95:2978-80. (Abstract) Liaw YF. Concurrent hepatitis B and C virus infection: Is hepatitis C virus stronger? J Gastroenterol Hepatol 2001;16:597-8. (Abstract) Liaw YF. Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. J Gastroenterol 2002;37 Suppl 13:65-8. (Abstract) Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995;22:1101-8. (Abstract) Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis 2008;12:733-46. (Abstract) Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280:36784-91. (Abstract) Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006;50:1813-22. (Abstract) Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6. (Abstract) Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterol 1992;102:2155-60. (Abstract) Liu CJ, Chen PJ, Lai MY et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology 2003:37:568-76. (Abstract) Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009:136(2):496-504. (Abstract) Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110-3. (Abstract) Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24. (Abstract) Lok AS, Gardiner DF, Lawitz E. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype null responders. J Hepatol 2011;54:536. Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM. Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 2006;442:831-5. (Abstract) Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterol 1994;106:1291-1300. (Abstract) Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004;101:4262-67. (Abstract) Malaguarnera M, Laurino A, Di F, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 2001;21:273-78. (Abstract) Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-20. (Abstract) Mangia A, Bandiera F, Montalto G, et al. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol 2010a;53:1000-5. (Abstract) Mangia A, Dalgard O, Minerva N, et al. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin. Aliment Pharmacol Ther 2010b;31:1346-53. (Abstract) Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatol 2008;47:43-50. (Abstract) Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17. (Abstract) Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010c;139:821-7, 827.e1. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. (Abstract) Manns M, Reesink H, Berg T, et al. Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antivir Ther 2011;16:1021-33. (Abstract) Manns M, Zeuzem S, Sood A, et al. Reduced Dose and Duration of Peginterferon Alfa-2b+Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (Redd 2/3 Trial). J Hepatol 2009;50:S59-S59. (Abstract) Manns M, Zeuzem S, Sood A, et al. Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in Patients With Genotype 2 and 3 Chronic Hepatitis C. J Hepatol 2011a;55:554-63. (Abstract) Manns MP, Felizarta F, Schiff E, et al. Overall safety profile of boceprevir plus peginterferon alfa-2b/ribavirin. J Hepatol 2011b;54:S183-S183. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006;55:1350-59. (Abstract) Marcellin P, Craxi A, Brandao-Mello CE, et al. A 72-Week Treatment Duration with Peginterferon Alfa-2a (40kd) (Pegasys®) Plus Ribavirin (Copegus®) Has a Favorable Risk:Benefit Ratio in Non-Responders to Pegylated Interferon Alfa-2b (12kd) Plus Ribavirin: Findings of the Multinational Repeat Study. Hepatol 2008;48:1147A-1147A. Marcellin P, Forns X, Goeser T, et al. Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C. Gastroenterology 2011;140:459-68 (Abstract) Marcellin P, Gish RG, Gitlin N, et al. Safety and efficacy of viramidine versus ribavirin in viser2: randomized, double-blind study in therapy-naive hepatitis C patients. J Hepatol 2010;52:32-8. (Abstract) Margin S, Craxi A, Fabiano C, et al. Hepatitis C viraemia in chronic liver disease: relationship to interferon alpha or corticosteroid treatment. Hepatol 1994;19:273-79. (Abstract) Marrone A, Zampino R, D'Onofrio M, et al. Combined interferon plus lamivudine treatment in young patients with dual HBV (HBeAg positive) and HCV chronic infection. J Hepatol 2004;41:1064-5. (Abstract) Matsumori A, Yutani C, Ikeda Y, Kawai S, Sasayama S. Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy. Lab Invest 2000;80:1137-42. (Abstract) Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745-52. (Abstract) Matthews GV, Pham ST, Hellard M, et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C. Clin Infect Dis. 2011;52:803-11. (Abstract) Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-25. (Abstract) McCown MF, Rajyaguru S, Kular S, et al. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53:2129-32. (Abstract) McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-36. (Abstract) McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38. (Abstract) McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterol 2002;123:1061-69. (Abstract) McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-303. (Abstract) McLauchlan J, Lemberg MK, Hope G, et al. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002;21:3980-88. (Abstract) Mederacke I, Wedemeyer H, Ciesek S, et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009;46:210-5. (Abstract) Medici MC, Furlini G, Rodella A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011;51:264-9. (Abstract) Meertens L, Bertaux C, Dragic T. Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol 2006;80:11571-78. (Abstract) Merican I, Sherlock S, McIntyre N, Dusheiko GM. Clinical, biochemical and histological features in 102 patients with chronic hepatitis C virus infection. Q J Med 1993;86:119-25. (Abstract) Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005;437:1167-72. (Abstract) Michelin BD, Muller Z, Stezl E, Marth E et al. Evaluation of the Abbott Real Time HCV assay for quantificative detection of hepatitis C virus RNA. J Clin Virol 2007;38:96-100. (Abstract) Mimms LT, Mosley JW, Hollinger FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993;307:1095-7. (Abstract) Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:961-69. (Abstract) Mohamed Ael S, al Karawi MA and Mesa GA Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404-6. (Abstract) Mohamed Ael S, al Karawi MA, Mesa GA. Dual infection with hepatitis C and B viruses: clinical and histological study in Saudi patients. Hepatogastroenterology 1997;44:1404-6. (Abstract) Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007;5:453-63. (Abstract) Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-44. (Abstract) Morota K, Fujinami R, Kinukawa H, et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009;157:8-14. (Abstract) Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterol 2008;134:416-23. (Abstract) Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology 2011;54:1538-46. (Abstract) Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatol 2010;52:822-32. (Abstract) Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-66. (Abstract) Nattermann J, Vogel M, Nischalke HD, et al. Genetic Variation in IL28B and Treatment-Induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C. J Infect Dis. 2011;203:595-601. (Abstract) Neff GW, Montalbano M, O'Brien CB, et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004;78:1303-07. Nelson DR, Gane EJ, Jacobson IM, Di Bisceglie AM, Alves K, Koziel MJ. VX-222/Telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR 12 interim analyses. Hepatology 2011;54:1442. Nettles RE, Gao M, Bifano M, et al. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, in press. Nolte FS, Fried MW, Shiffman ML, et al. Prospective multicenter clinical evaluation of AMPLICOR and COBAS AMPLICOR hepatitis C virus tests. J Clin Microbiol 2001;39:4005-12. (Abstract) Nomura H, Tanimoto H, Kajiwara E, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004;19:1312-7. (Abstract) Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994;330:744-50. (Abstract) Opravil M, Sasadeusz J, Cooper DA, et al. Effect of baseline CD4 cell count on the efficacy and safety of peg-interferon-a 2a (40 kd) + ribavirin in patients with HIV-HCV coinfection. J Acquir Immune Def Syndr 2008;47:36-49. (Abstract) Ozaslan E, Purnak T. Controversies about occult hepatitis B virus infection. World J Gastroenterol 2009;15:4986-7. (Abstract) Pallas JR, Farinas-Alvarez C, Prieto D, et al. Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users. Eur J Epidemiol 1999;15:699-704. (Abstract) Pariante CM, Landau S, Carpiniello B. Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis. N Engl J Med 2002;347:148-49. (Abstract) Pawlotsky JM, Chevalier S, McHutchinson JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98. (Abstract) Pawlotsky JM, Flisiak R, Rasenack J, et al. Once daily alisporivir interferon-free regimens achieve high rates of early HCV clearance in previously untreated patients with HCV gentoype 2 or 3. Hepatology 2011;54:1074. Pawlotsky JM. Use and interpretation of hepatitis C virus diagnostic assays. Clin Liver Dis 2003b;7:127-37. (Abstract) Paydas S, Seyrek N, Gonlusen G, Sagliker Y. The frequencies of hepatitis B virus markers and hepatitis C virus antibody in patients with glomerulonephritis. Nephron 1996;74:617-19. (Abstract) Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatol 2007;46:1688-94. (Abstract) Perry W, Hilsabeck RC, Hassanein TI. Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci 2008;53:307-21. (Abstract) Peters L, Mocroft A, Soriano V, et al and the EuroSIDA Study Group. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009;50:457-63. (Abstract) Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-42. (Abstract) Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41. (Abstract) Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-30. (Abstract) Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occluding is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009;457:882-86. (Abstract) Pockros P, Jensen DM, Tsai N. First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis of the JUMP-C trial. J Hepatol 2011;54:538. Pockros P, Nelson D, Godofsky E, et al. High relapse rate seen at week 72 for patients treated with R1626 combination therapy. Hepatol 2008a;48:1349-50. (Abstract) Pockros PJ, Nelson D, Godofsky E, et al. R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatol 2008b;48:385-97. (Abstract) Pockros PJ, Shiffman ML, Schiff ER, et al and the PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatol 2004;40:1450-8. (Abstract) Pol S, Aerssens J, Zeuzem S, et al. Similar SVR rates in IL28b cc, ct or tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the realize study. J Hepatol 2011a;54:S6-S7. Pol S, Roberts SK, Andreone P, et al. Efficacy and safety of telaprevir-based regimens in cirrhotic patients with hcv genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the realize phase III study. Hepatology 2011b;54:374A-375A. Poordad F, Bronowicki JP, Gordon SC, et al. Il28b polymorphism predicts virologic response in patients with hepatitis c genotype 1 treated with boceprevir (boc) combination therapy. J Hepatol 2011;54:S6-S6. Poordad F, McCone J, Bacon B, et al. Boceprevir combined with peginterferon alfa-2B/ribavirin for treatment-naive patients with hepatitis C virus genotype (G) 1: SPRINT-2 final results. Hepatol 2010;50:S402. Poordad F, McCone JJ, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206. (Abstract) Potthoff A, Berg T, Wedemeyer H, et al. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009;44:1487-90. (Abstract) Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008;49:688-94. (Abstract) Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34. (Abstract) Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32. (Abstract) Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterol 2009;136:1618-28. (Abstract) Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13:547-51. (Abstract) Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C coinfection. Lancet 2003;362:1708-13. (Abstract) Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006;43:100-7. (Abstract) Raison CL, Woolwine BJ, Demetrashvili MF, et al. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007;25:1163-74. (Abstract) Rallón NI, Soriano V, Naggie S, et al. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. AIDS. 2011;25:1025-33. (Abstract) Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45. (Abstract) Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010,138:1338-1345. (Abstract) Reddy GA, Dakshinamurthy KV, Neelaprasad P, et al. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol 2005;23:41-3. (Abstract) Reddy GA, Dakshinamurthy KV, Neelaprasad P, et al. Prevalence of HBV and HCV dual infection in patients on haemodialysis. Indian J Med Microbiol 2005;23:41-3. (Abstract) Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-29. (Abstract) Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterol 2010;138:913-21. (Abstract) Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterol 2006;131:997-1002. (Abstract) Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatol 2005;41:832-5. (Abstract) Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-80. (Abstract) Resino S, Asensio C, Bellón JM, et al. Diagnostic accuracy of the APRI, FIB-4, and the Forns index for predicting liver fibrosis in HIV/HCV-coinfected patients: A validation study. J Infect. 2011;63:402-5. (Abstract) RKI. Hepatitis C: RKI-Ratgeber Infektionskrankheiten. Epidemiologisches Bulletin 2004;17:141. Roberts SK, Andreone P, Pol S, et al. Impact of anemia and ribavirin dose reduction on svr to a telaprevir-based regimen in patients with hcv genotype 1 and prior peginterferon/ribavirin treatment failure in the phase III realize study. Hepatology 2011;54:1007A-1008A. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61. (Abstract) Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9:82-8. (Abstract) Rockstroh JK, Mocroft A, Soriano V, et al. Influence of Hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005;192:992-1002. (Abstract) Rockstroh JK. Hot topics in HIV and hepatitis coinfection: noninvasive diagnosis of liver disease, liver transplantation, and new drugs for treatment of hepatitis coinfection. HIV Clin Trials 2009b;10:110-5. (Abstract) Rodriguez-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004;77:190-94. (Abstract) Rodriguez-Novoa S, Morello J, Gonzalez M, et al. Increase in serum bilirubin in HIV/hepatitis C virus coinfected patients on atazanavir therapy following initiation of pegylated interferon and ribavirin. AIDS 2008;22:2535-7. (Abstract) Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: Final results of the PARADIGM study. AASLD 2009, Abstr 1561. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterol 2009;136:856-62. (Abstract) Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15. (Abstract) Saadoun D, Asselah T, Resche-Rigon M, et al. Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C. Hepatol 2006;43:1337-45. (Abstract) Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116:326-34. (Abstract) Saadoun D, Resche-Rigon M, Sene D, Perard L, Piette JC, Cacoub P. Rituximab combined with Peg-Interferon-Ribavirin in refractory HCV-associated cryoglobulinemia vasculitis. Ann Rheum Dis 2008;67:1431-36. (Abstract) Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77. (Abstract) Sabato MF, Shiffman ML, Langley MR, et al. Comparison of Performance Characteristics of three Real Time Reverse Transcription-PCR test systems for detection and quantification of hepatitis C virus. J Clin Microbiol 2007;45:2529-36. (Abstract) Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002;36:1285-91. (Abstract) Sagnelli E, Coppola N, Scolastico C, et al. HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001;64:350-5. (Abstract) Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterol 2006;131:451-60. (Abstract) Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10. (Abstract) Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol 2005;42:329-33. (Abstract) Sarrazin C, Berg T, Ross RS, et al. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010a;48:289-351. (Abstract) Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol 2001;39:2850-5. (Abstract) Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterol 2007a;132:1767-77. (Abstract) Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterol 2007b;132:1270-8. (Abstract) Sarrazin C, Schwendy S, Moller B, et al. Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Gastroenterology 2011a;141:1656-64. (Abstract) Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011b;54:415-21. (Abstract) Sarrazin C, Berg T, Cornberg M, et al. Expertenempfehlungen zur Triple-Therapie der HCV Infektion mot Boceprevir und Telaprevir. Z Gastroenterol 2012:50:57-72. (Abstract) Sarrazin C, Teuber G, Kokka R, et al. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000;32:818-23. (Abstract) Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010b;138:447-62. (Abstract) Sarrazin C. Highly sensitive hepatitis C virus RNA detection methods: molecular backgrounds and clinical significance. J Clin Virol 2002;25:S23-9. (Abstract) Sato S, Fujiyama S, Tanaka M, et al. Coinfection of hepatitis C virus in patients with chronic hepatitis B infection. J Hepatol 1994;21:159-66. (Abstract) Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002;21:5017-25. (Abstract) Schaefer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review. Int J Methods Psychiatr Res 2007a;16:186-201. (Abstract) Schaefer M, Engelbrecht MA, Gut O, et al. Interferon alpha [IFNalpha] and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiat 2002;26:731-46. (Abstract) Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004;99:1167-75. (Abstract) Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatol 2007b;46:991-98. (Abstract) Schaefer M, Mauss S. Clinical management of Interferon-alpha-associated psychiatric side effects during hepatitis C treatment in patients with drug addiction. Cur Drug Abuse Rev 2008;1:177-87. (Abstract) Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatol 2003;37:443-51. (Abstract) Schaefer M, Schwaiger M, Garkisch AS, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42:793-8. (Abstract) Schiff E, Poordad E, Jacobson I, et al. Boceprevir (B) combination therapy in null responders (NR): Response dependent on interferon responsiveness. J Hepatol 2008;48:S46-S46. Schmidt AJ, Rockstroh JK, Vogel M, et al. Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany--a case-control study. PLoS One 2011;6:e17781. (Abstract) Schutten M, Fries E, Burghoorn-Maas C, Niesters HG. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J Clin Virol 2007;40:99-104. (Abstract) Senturk H, Tahan V, Canbakan B, et al. Chronic hepatitis C responds poorly to combination therapy in chronic hepatitis B carriers. Neth J Med 2008;66:191-5. (Abstract) Serfaty L, Forns X, Goeser T, et al. No impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in hcv genotype 1 treatment-naive patients: sub-analysis of c208 study. Hepatology 2010;52:705A-705A. Seyam MS, Freshwater DA, O'Donnell K, Mutimer DJ. Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C. J Viral Hepat 2005;12:531-5. (Abstract) SeyedAlinaghi S, Jam S, Mehrkhani F, et al. Hepatitis-C and hepatitis-B co-infections in patients with human immunodeficiency virus in Tehran, Iran. Acta Med Iran 2011; 49:252-7. (Abstract) Shavinskaya A, Boulant S, Penin F, et al. The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J Biol Chem 2007;282:37158-69. (Abstract) Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24. (Abstract) Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatol 2010;52:S401. (Abstract) Sherman KE, Rockstroh JK, Dieterich DT, et al. Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Coinfected Patients: A 24-Week Treatment Interim Analysis. The 62nd Annual Meeting of the American Association for the Study of Liver Diseases 2011, San Francisco, USA. Abstract LB-8. Sherman KE, Sulkowski M, Zoulim F, Alberti A. Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treatetd with telaprevir-based regimens: interim analysis of the extend study. Hepatology 2011;54:1471. Sherman KE, Sulkowski MS, Zoulim F, et al. Follow-up of svr durability and viral resistance in patients with chronic hepatitis c treated with telaprevir-based regimens: interim analysis of the extend study. Hepatology 2011;54:485A-486A. Shi ST, Polyak SJ, Tu H, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virol 2002;292:198-210. (Abstract) Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterol 2004;126:1015-23. (Abstract) Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998;28:382-89. (Abstract) Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatol 2007;46:371-9. (Abstract) Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34. (Abstract) Silva M, Kasserra C, Gupta S, Treitel MA, Hughes E, O'Mara E. Antiviral Activity of Boceprevir Monotherapy in Treatment-Naive Subjects With Chronic Hepatitis C Genotype 2/3. APASL 2011. Silvestri F, Barillari G, Fanin R, et al. Hepatitis C virus infection among cryoglobulinemic and non-cryoglobulinemic B-cell non-Hodgkin's lymphomas. Haematologica 1997;82:314-7. (Abstract) Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73. (Abstract) Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1-5. (Abstract) Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004;2:469-73. (Abstract) Sulkowski M, Pol S, Cooper C, et al. Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co.Infected Patients. Infectious Diseases Society of America, 49th Annual Meeting 2011, Boston, USA. Abstract LB-37. Sulkowski MS, Poordad F, Manns MP, et al. Anemia during treatment with peginterferon alfa-2b/ribavirin with or without boceprevir is associated with higher svr rates: analysis of previously untreated and previous-treatment-failure patients. J Hepatol 2011;54:S194-S195. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011. (Abstract) Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatol 2009;50:1709-18. (Abstract) Svirtlih N, Jevtovic D, Simonovic J, et al. Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C. Hepatogastroenterology 2007;54:2324-7. (Abstract) Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593-601. (Abstract) Swain MG, Lai MY, Shiffman ML, et al. Durable sustained virological response after treatment with peginterferon alpha-2a (PEGASYS®) alone or in combination with ribavirin (COPEGUS®): 5-year follow-up and the criteria of a cure. J Hepatol 2007;46:S3-S3. Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation. J Viral Hepat 2011;18:e381-93. (Abstract) Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005;435:374-9. (Abstract) The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2011;25:399-409. (Abstract) Thompson AJ, Patel K, Chuang WL, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2012;61:128-34. (Abstract) Thomson E, Fleming VM, Main J, et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut. 2011;60:837-45. (Abstract) Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, McClure MO. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009;23:89-93. (Abstract) Thomssen R, Bonk S, Propfe C, et al. Association of hepatitis C virus in human sera with lipoprotein. Med Microbiol Immunol 1992;181:293-300. (Abstract) Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010;139:1586-92. (Abstract) Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatol 1995;22:1374-78. (Abstract) Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38. (Abstract) Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002:2:479-86. (Abstract) Tran HA, Jones TL, Ianna EA, Reeves GE. The natural history of interferon-alpha induced thyroiditis in chronic hepatitis c patients: a long term study. Thyroid Res 2011;4:2. (Abstract) Tsukiyama-Kohara K, Iizuka N, Kohara M, et al. Internal ribosome entry site within hepatitis C virus RNA. J Virol 1992;66:1476-83. (Abstract) Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, et al. The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomes. J Viral Hepat. 2010; 17:569-77. (Abstract) Utili R, Zampino R, Bellopede P, et al. Dual or single hepatitis B and C virus infections in childhood cancer survivors: long-term follow-up and effect of interferon treatment. Blood 1999;94:4046-52. (Abstract) Valentine AD, Meyers CA. Successful treatment of interferon-alpha-induced mood disorder with nortriptyline. Psychosomat 1995;36:418-9. (Abstract) Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468-73. (Abstract) Van Heeswijk R, Garg V, Boogaerts G, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. 51st ICAAC Chicago USA 2011, Abstract A1-1738a. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Faruki H. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. J Viral Hepat 1997;4:101-06. (Abstract) Vehrmeren J, Kau A, Gärtner B, Göbel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR based assays (Abbott RealTime HCV, COBAS AmpliPrep/COBAS TaqMan) and one signal amplification assay (VERSANT HCV RNA 3.0) for HCV RNA detection and quantification. J Clin Microbiol 2008;46:880-91. (Abstract) Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84. (Abstract) Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006;42:262-70. (Abstract) Vertex Pharmaceuticals Incorporated. Prescribing Information Incivek (telaprevir). PDF, 23 pages, accessed February 25, 2012. Vertex Pharmaceuticals. "65% of people whose prior treatment for hepatitis C was unsuccessful achieved SVR (viral cure) with telaprevir-based therapy in phase 3 REALIZE study". Press Release 2010 http://investors.vrtx.com/releasedetail.cfm?releaseID=505239. Vezali E, Elefsiniotis I, Mihas C, Konstantinou E, Saroglou G. Thyroid dysfunction in patients with chronic hepatitis C: Virus-or therapy-related? J Gastroenterol Hepatol 2009;24:1024-29. (Abstract) Vierling JM, Flamm SL, Gordon SC, et al. Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the provide study. Hepatology 2011;54:796A-797A. Villa E, Grottola A, Buttafoco P, et al. High doses of alpha-interferon are required in chronic hepatitis due to coinfection with hepatitis B virus and hepatitis C virus: long term results of a prospective randomized trial. Am J Gastroenterol 2001;96:2973-7. (Abstract) Vogel M, Ahlenstiel G, Hintsche B, et al. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals. Eur J Med Res 2010; 15:102-111. (Abstract) Vogel M, Deterding K, Wiegand J, et al, German Hepatitis Group Hep-Net. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009a;49:317-9. Vogel M, Rockstroh JK. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009b;4:171-5. (Abstract) Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother. 2010;65:4-9. (Abstract) Vogel M, Voigt E, Michaelis HC et al.: Management of drug-to-drug interactions between cyclosporin A and the protease inhibitor saquinavir/ritonavir in liver transplanted HIV-infected patients. Liver Transplant 2004;10:939-44. (Abstract) von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterol 2005;129:522-27. (Abstract) Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatol 2010;51:1912-21. (Abstract) Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6. (Abstract) Walewski JL, Keller TR, Stump DD, et al. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001;7:710-21. (Abstract) Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. Strong association of Hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004;39:790-96. (Abstract) Washburn ML, Bility MT, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011;140:1334-44. (Abstract) Weiner SM, Berg T, Berthold C, et al. A clinical and virological study of hepatitis C virus-related cryoglobulinemia in Germany. J Hepatol 1998;29:375-84. (Abstract) Weissenborn K, Ennen JC, Bokemeyer M, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624-30. (Abstract) Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol 2005;78:138-141. (Abstract) Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol 2008;9:R16. (Abstract) Weltman MD, Brotodihardio A, Crewe EB, et al. Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. J Viral Hepat 1995;2:39-45. (Abstract) Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001;48:378-83. (Abstract) White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol 2008;49:831-44. (Abstract) WHO, Factsheet No 164, June 2011. http://goo.gl/5m3sY, accessed 10.01.2012. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatol 2006;43:250-56. (Abstract) Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study. Hepatology 2000;32:91-6. (Abstract) Wietzke P, Schott P, Braun F, et al. Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver 1999;19:348-53. (Abstract) Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007;20:23-38. (Abstract) Wong VS, Egner W, Elsey T, Brown D, Alexander GJ. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996;104:25-31. (Abstract) Wu JC, Chen CL, Hou MC, et al. Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations oft he polymerase chain reaction. Hepatology 1994;19:836-40. (Abstract) Yalcin K, Degertekin H, Yildiz F, et al. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800. (Abstract) Yalcin K, Degertekin H, Yildiz F, et al. A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin. J Gastroenterol 2003;38:796-800. (Abstract) Younossi ZM, Nader FH, Bai C, et al. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008;15:370-78. (Abstract) Yu JW, Sun LJ, Zhao YH, Kang P, et al. Analysis of the efficacy of treatment with peginterferon ?-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009;29:1485-93. (Abstract) Yu X, Qiao M, Atanasov I, et al. Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology 2007;367:126-34. (Abstract) Zarski JP, Bohn B, Bastie A, et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998;28:27-33. (Abstract) Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28. (Abstract) Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28. (Abstract) Zeuzem S, Arora S, Bacon B, Box T, Charlton M. Pegylated interferon-lambda shows superior viral response with improved safety and tolerability versus pegIFN-alfa-2a in hCV patients (G1/2/3/4): merge phase IIB trhough week 12. J Hepatol 2011;54:538. Zeuzem S, Asselah T, Angus P, et al. Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection. Gastroenterology 2011:141:2047-55. (Abstract) Zeuzem S, Berg, T, Moeller, B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16:75-90. (Abstract) Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or pegIFN/RBV for up to 28 days in treatment naive , genotype 1 HCV subjects. Hepatol 2010a;50:S106. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C. Hepatology 2011, in press. (Abstract) Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103. (Abstract) Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterol 2004b;127:1724-32. (Abstract) Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004a;40:993-99. (Abstract) Zeuzem S, Sulkowski M, Lawitz E, et al. Efficacy and Safety of Albinterferon Alfa-2b in Combination with Ribavirin in Treatment-Naive, Chronic Hepatitis C Genotype 1 (Chc G1) Patients. J Hepatol 2009;50:S377-S377. Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterol 2010b;13:1257-66. (Abstract) Zhou J, Dore GJ, Zhang F, et al. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22:1510-8. (Abstract) Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Extrahepatic manifestations of the Hepatitis C Virus infection: a general overview and guidelines for clinical approach. Dig Liver Dis 2007a;39:2-17. (Abstract) Zignego AL, Fontana R, Puliti S, et al. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997;51:313-8. (Abstract) Zignego AL, Giannelli F, Marrocchi ME, et al. T(14;18) translocation in chronic hepatitis C virus infection. Hepatol 2000;31:474-9. (Abstract) Zimmer V, Lammert F. Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best Pract Res Clin Gastroenterol. 2011 Apr;25:269-80. (Abstract)

Free Medical Books 108085 Number of FP Guides downloaded since March 2011

Design: Attilio Baghino

Disclaimer

© BSK